These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 27463810)

  • 1. Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Cheng T; Shuang WB; Jia DD; Zhang M; Tong XN; Yang WD; Jia XM; Li S
    PLoS One; 2016; 11(7):e0159307. PubMed ID: 27463810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
    Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison.
    Cruz F; Danchenko N; Fahrbach K; Freitag A; Tarpey J; Whalen J
    J Med Econ; 2023; 26(1):200-207. PubMed ID: 36647624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
    Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
    Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis.
    Wu SJ; Xu YQ; Gao ZY; Wang ZP; Zhao F; Liu L; Wang S
    Ren Fail; 2019 Nov; 41(1):937-945. PubMed ID: 31599184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity.
    Apostolidis A; Thompson C; Yan X; Mourad S
    World J Urol; 2013 Dec; 31(6):1469-74. PubMed ID: 23160758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis.
    Zhou X; Yan HL; Cui YS; Zong HT; Zhang Y
    Chin Med J (Engl); 2015 Apr; 128(7):963-8. PubMed ID: 25836619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology.
    Ginsberg D; Cruz F; Herschorn S; Gousse A; Keppenne V; Aliotta P; Sievert KD; Brin MF; Jenkins B; Thompson C; Lam W; Heesakkers J; Haag-Molkenteller C
    Adv Ther; 2013 Sep; 30(9):819-33. PubMed ID: 24072665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study.
    Kennelly M; Dmochowski R; Schulte-Baukloh H; Ethans K; Del Popolo G; Moore C; Jenkins B; Guard S; Zheng Y; Karsenty G;
    Neurourol Urodyn; 2017 Feb; 36(2):368-375. PubMed ID: 26607743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
    Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
    J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review.
    Zhang R; Xu Y; Yang S; Liang H; Zhang Y; Liu Y
    Int Braz J Urol; 2015; 41(2):207-19. PubMed ID: 26005961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact.
    Nitti V; Haag-Molkenteller C; Kennelly M; Chancellor M; Jenkins B; Schurch B
    Medicine (Baltimore); 2023 Jul; 102(S1):e32377. PubMed ID: 37499088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse Effects of Intravesical OnabotulinumtoxinA Injection in Patients with Idiopathic Overactive Bladder or Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Studies.
    Yu PH; Wang CC
    Toxins (Basel); 2024 Aug; 16(8):. PubMed ID: 39195753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study.
    Denys P; Del Popolo G; Amarenco G; Karsenty G; Le Berre P; Padrazzi B; Picaut P;
    Neurourol Urodyn; 2017 Feb; 36(2):457-462. PubMed ID: 26756554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.
    Sussman D; Patel V; Del Popolo G; Lam W; Globe D; Pommerville P
    Neurourol Urodyn; 2013 Mar; 32(3):242-9. PubMed ID: 22965657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Who Completed 4 Years of Treatment.
    Rovner E; Kohan A; Chartier-Kastler E; Jünemann KP; Del Popolo G; Herschorn S; Joshi M; Magyar A; Nitti V
    J Urol; 2016 Sep; 196(3):801-8. PubMed ID: 27091236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis.
    Kennelly M; Dmochowski R; Ethans K; Karsenty G; Schulte-Baukloh H; Jenkins B; Thompson C; Li D; Haag-Molkenteller C
    Urology; 2013 Mar; 81(3):491-7. PubMed ID: 23290144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity.
    Chancellor MB; Patel V; Leng WW; Shenot PJ; Lam W; Globe DR; Loeb AL; Chapple CR
    Neurology; 2013 Aug; 81(9):841-8. PubMed ID: 23892704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin.
    Popat R; Apostolidis A; Kalsi V; Gonzales G; Fowler CJ; Dasgupta P
    J Urol; 2005 Sep; 174(3):984-9. PubMed ID: 16094019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders.
    Mangera A; Apostolidis A; Andersson KE; Dasgupta P; Giannantoni A; Roehrborn C; Novara G; Chapple C
    Eur Urol; 2014 May; 65(5):981-90. PubMed ID: 24239446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.